Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly E Dooley

Showing results (31-40 of 170) with videos related to

Pageof 17
Sort By:
Open Forum Infectious Diseases|August 16, 2021
Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency VirusNicky J Mehtani, Sarah Puryear, Paul Pham, et al.
The American Journal of Tropical Medicine and Hygiene|April 7, 2009
Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosisKelly E Dooley, Tania Tang, Jonathan E Golub, et al.
The AAPS Journal|October 15, 2015
Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based AnalysisElin M Svensson, Chayan Acharya, Björn Clauson, et al.
Chest|April 12, 2002
A 39-year-old man with hip pain and respiratory failureKelly E Dooley, Saurabh R Sinha, Edward Haponik, et al.
British Journal of Clinical Pharmacology|November 17, 2022
Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic modelAida N Kawuma, Roeland E Wasmann, Kelly E Dooley, et al.
Archives of Toxicology|April 10, 2019
Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatmentHyejeong Hong, Kelly E Dooley, Laura E Starbird, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2020
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis ModelKristina M Bigelow, Rokeya Tasneen, Yong S Chang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2002
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosisKelly E Dooley, Jonathan Golub, Fernando S Goes, et al.
American Journal of Respiratory and Critical Care Medicine|October 20, 2020
Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal ActivitySolomon P le Roux, Caryn Upton, Naadira Vanker, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2022
Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with RifampicinAida N Kawuma, Roeland E Wasmann, Kelly E Dooley, et al.
Pageof 17

Showing results (31-40 of 170) with videos related to

Sort By:
Pageof 17
Open Forum Infectious Diseases|August 16, 2021
Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency VirusNicky J Mehtani, Sarah Puryear, Paul Pham, et al.
The American Journal of Tropical Medicine and Hygiene|April 7, 2009
Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosisKelly E Dooley, Tania Tang, Jonathan E Golub, et al.
The AAPS Journal|October 15, 2015
Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based AnalysisElin M Svensson, Chayan Acharya, Björn Clauson, et al.
Chest|April 12, 2002
A 39-year-old man with hip pain and respiratory failureKelly E Dooley, Saurabh R Sinha, Edward Haponik, et al.
British Journal of Clinical Pharmacology|November 17, 2022
Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic modelAida N Kawuma, Roeland E Wasmann, Kelly E Dooley, et al.
Archives of Toxicology|April 10, 2019
Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatmentHyejeong Hong, Kelly E Dooley, Laura E Starbird, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2020
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis ModelKristina M Bigelow, Rokeya Tasneen, Yong S Chang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2002
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosisKelly E Dooley, Jonathan Golub, Fernando S Goes, et al.
American Journal of Respiratory and Critical Care Medicine|October 20, 2020
Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal ActivitySolomon P le Roux, Caryn Upton, Naadira Vanker, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2022
Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with RifampicinAida N Kawuma, Roeland E Wasmann, Kelly E Dooley, et al.
Pageof 17